骨髓单个核细胞Coombs试验在免疫相关性血细胞减少症中的诊断意义

目的 研究骨髓单个核细胞抗人球蛋白试验(Coombs试验)对免疫相关性血细胞减少症的诊断价值.方法 采用骨髓单个核细胞(BMMNC)悬液取代经典Coombs试验的外周血红细胞悬液,即骨髓单个核细胞Coombs(BMMNC-Coombs)试验检测21例临床拟诊免疫相关性血细胞减少(IRH)或全血细胞减少(IRP)症患者,并以20例明确诊断的血细胞减少患者作为对照.结果 21例拟诊IRH/IRP患者中BMMNC-Coombs试验阳性14例,阳性率66.7%.对照组20例BMM-NC-Coombs试验均阴性.BMMNC-Coombs试验阳性患者经临床应用糖皮质激素等免疫抑制荆均产生了显著疗效.结论 BMMNC-Coombs试验对IRH/IRP的诊断具有较高的灵敏度和特异度,且简便可行,易于推广应用.     

骨髓单个核细胞Coombs试验(+)血细胞减少患者骨髓巨噬细胞数量及功能的研究

目的 探讨骨髓单个核细胞Coombs(BMMNC-Coombs)试验(+)血细胞减少患者骨髓巨噬细胞(Mφ)数量、功能及其临床意义.方法 采用流式细胞术(FACS)检测61例BMMNC-Coombs试验(+)血细胞减少患者、10例重型再生障碍性贫血(SAA)患者及13名正常对照骨髓Mφ(CD68或CD45阳性)数量并通过鸡红细胞(CRBC)吞噬试验检测Mφ功能,并分析其临床意义.结果 BMMNC.Coombs试验(+)血细胞减少患者其Mφ百分率、吞噬率及吞噬指数[(0.57±0.30)%、(37.56±15.20)%和0.75±0.34]均高于SAA组[(0.46±0.08)%、(28.26±10.46)%和0.59±0.39]及正常对照组[(0.44±0.69)%、(25.63±14.75)%和0.55 ± 0.16](P<0.05);且Mφ百分率与Mφ吞噬率及吞噬指数均呈正相关(r=0.43,P<0.01;r=0.40,P<0.01).根据Mφ数量将患者分为A组(Mφ≥10.5%)和B组(Mφ<0.5%),A组34例患者中32例(94.12%)自身抗体为IgG型,B组27例患者中仅2例(7.41%)自身抗体为IgG型;A组患者Mφ的吞噬率和吞噬指数[(46.62±13.38)%和0.91±0.36]显著高于B组患者[(28.67±12.59)%和0.61 ± 0.30](P<0.05),而B组患者与AA及正常对照组相比差异无统计学意义(P>0.05).将34例自身抗体IgG型患者分为Mφ高(≥0.75%)、低水平(<0.75%)两组,Mφ低水平组25例患者骨髓均仪能榆测到一系细胞与IgG结合,Mφ高水平组9例患者中8例能检测到二系细胞结合IgG,1例骨髓三系细胞均结合有IgG;Mφ高水平组患者中Mφ的吞噬率及吞噬指数[(60.22±12.51)%、1.23±0.23]显著高于Mφ低水平组[(43.32±9.24)%、0.84±0.24](P<0.05);Mφ高水平组患者外周血红细胞、血红蛋白、血小板计数均显著低于Mφ低水平组(P<0.05);Mφ高水平组网织红细胞比例、胆红素水平及胸骨红系比例均显著高于Mφ低水平组(P<0.05).结论 IgG型BMMNC-Coombs试验(+)血细胞减少患者骨髓Mφ数量增多,功能增强;IgG A身抗体阴性的BMMNC-Coombs试验(+)血细胞减少患者多有lgM型自身抗体或冷抗体,其骨髓损伤过程无Mφ参与.     

化疗对造血微环境的影响及化疗后回输自体骨髓基质细胞对造血功能恢复的作用

目的观察化疗对造血祖细胞、造血微环境的影响,化疗后回输体外扩增的自体骨髓基质细胞(ABMSC)对造血功能恢复的作用.方法对化疗患者进行骨髓CFU-GM、CFU-E、BFU-E及基质细胞集落(CFU-F)培养、长期骨髓培养,观察基质层融合情况,计算基质层覆盖率及完全融合时间.长期化疗的10例患者进行自身前后对照,在同一化疗方案下,单纯化疗与化疗后回输体外扩增的ABMSC[(1.1～8.7)×103/次]作对比,观察两者造血恢复情况.结果①长期化疗组的CFU-GM、BFU-E、CFU-E、CFU-F显著低于正常对照组及短期化疗组,后两组差异无显著性;②三组基质层覆盖率及完全融合时间差异无显著性;③长期化疗组ABMSC输注后的CFU-GM、CFU-E、BFU-E、CFU-F显著高于未输注组;④输注ABMSC后白细胞计数及血小板计数降至最低点的值显著高于未输注组,前者白细胞计数及血小板计数恢复正常时间较后者明显缩短;⑤基质细胞回输过程及输后临床观察无不良反应.结论长期化疗明显损伤造血祖细胞、基质祖细胞,但对骨髓基质细胞融合功能无明显影响,化疗后给予ABMSC可加速造血功能的恢复.     

尿毒症患者红细胞生成抑制因子的实验研究

目的本文采用甲基纤维素细胞培养的方法,分析尿毒症患者血清及超滤液对小鼠骨髓红系造血祖细胞集落形成的影响,初步探讨红细胞生成抑制因子的存在、其相对分子质量大小及高通量透析器与普通低通量透析器对其清除的不同影响。方法选择北京朝阳医院肾内科12例尿毒症肾性贫血未透析患者为实验组,另选正常健康体检者12例为正常对照组,将实验组、正常对照组血清及应用F80透析器对实验组患者采用单纯超滤的方法所得超滤液(A组)、并将上述超滤液再用F6透析器进行循环超滤所得的超滤剩余液(B组)及F6超滤液(C组)分别稀释成不同终浓度,采用甲基纤维素细胞培养的方法与小鼠骨髓细胞进行培养,对比不同浓度血清组红系集落形成单位(CFU-E)、红系爆式形成单位(BFU-E)的集落数,A、B、C3组超滤液在相同浓度时CFU-E、BFU-E集落的数量。结果在实验组中,与血清浓度为0的浓度组相比,与各浓度组血清共同培养的小鼠骨髓CFU-E和BFU-E的集落数均明显减少,且随血清浓度的增加,小鼠骨髓CFU-E和BFU-E的集落数逐渐减少,各浓度组间差异有显著性(P<0.05);在A、B、C3组的各组内,与超滤液浓度为0的浓度组相比,与各浓度组超滤液共同培养的小鼠骨髓CFU-E和BFU-E的集落数均明显减少,且随超滤液浓度的增加小鼠骨髓CFU-E和BFU-E的集落数逐渐减少,各浓度组间差异有显著性(P<0.05);相同浓度时,与A组滤过液共同培养的小鼠骨髓CFU-E和BFU-E的集落数较B组、C组均明显减少;B组、C组两组之间差异无显著性(P>0.05)。结论尿毒症患者血中存在红细胞生成抑制因子,其对红系造血祖细胞的抑制作用具有剂量依赖性;红细胞生成抑制因子既可有大、中分子物质也有小分子物质;高通量透析器较普通低通量透析器能更有效清除红细胞生成抑制因子。     

免疫相关全血细胞减少患者骨髓造血祖细胞增殖功能及辅助性T淋巴细胞功能观察

目的　了解与免疫相关全血细胞减少患者骨髓造血祖细胞增殖分化功能以及辅助性T(Th)淋巴细胞在此类患者发病中的作用。方法　采用甲基纤维素法培养 2 5例初诊、15例治疗后血常规恢复的免疫相关全血细胞减少患者和 10名正常人的CFU GM、CFU E、BFU E ;采用RT PCR方法 ,检测 2 5例初诊、15例治疗后血常规恢复的免疫相关全血细胞减少患者、19例其他全血细胞减少症患者和 10名正常人未经体外刺激的骨髓单个核细胞 (BMMNC)中Th1细胞的代表因子IFN γ、IL 2和Th2细胞的代表因子IL 4、IL 10的基因表达。结果　初诊组、治疗后血常规恢复正常的免疫相关全血细胞减少患者组、正常对照组BMMNC培养CFU E、CFU GM、BFU E产率 ,三组差异均无显著性 (P均 >0 .0 5 ) ,Th2型细胞因子IL 4、IL 10mRNA的表达在初诊组明显增高 ,与正常对照组比较 ,P均 <0 .0 1;经治疗血常规恢复正常后趋于正常 ,与正常对照组比较 ,P均 >0 .0 5。Th1型细胞因子IFN γ、IL 2mRNA的表达在所有免疫相关全血细胞减少患者均无增高 ,与正常对照组比较 ,P均 >0 .0 5。结论　引起免疫相关全血细胞减少患者全血细胞减少的原因可能并非骨髓造血祖细胞本身质的异常 ,而是造血祖细胞以外的因素 ;Th细胞亚群功能失衡、Th2细胞功能亢进可能是此类患者B淋巴细     

成人急性白血病中p73基因的表达及意义

目的:检测并分析p73在急性白血病(AL)患者骨髓单个核细胞(BMMNC)中的表达情况,初步探讨p73与p53的相关性以及p73和细胞抗原表达的相关性,从而分析p73在AL中的临床意义.方法:应用逆转录聚合酶链反应(RT-PCR)检测AL组和对照组BMMNC p73与p53的表达情况.采用流式细胞术对AL BMMNC细胞表面及浆内分化抗原检测,分析p73与细胞抗原的相关性.结果:ALL初诊组p73阳性表达率低于ALL-CR组和对照组(P＜0.05),AML初诊组p73阳性表达率明显高于AML-CR组和对照组(P＜0.05).30例AML初诊组中p73与p53、CD2呈正相关,与MPO(髓过氧化物酶)呈负相关(r=0.481,P＜0.01;r=0.447,P＜0.05;r=-0.492,P＜0.01).20例ALL初诊组中,p73与p53无相关性(P＞0.05),p73与细胞抗原表达亦无相关性(P＞0.05).结论:p73在AL发生发展和预后中可能发挥重要作用.     

骨髓增生异常综合征患者巨核细胞系统改变的探讨

目的探讨骨髓增生异常综合征(MDS)患者的巨核细胞系统的改变与急性非淋巴细胞白血病(ANLL)患者的巨核细胞系统改变的关系.方法观察22例MDS患者的骨髓涂片及27例ANLL患者的巨核细胞的形态和数量,结合全自动血液分析仪对血小板各参数检测结果的分析.结果 MDS患者骨髓中产生血小板巨核细胞与正常对照组相比显著减少(P＜0.05),骨髓涂片的巨核细胞计数较正常对照组明显减少(P＜0.05),而与ANLL患者相比较无显著的差异(P＜0.05).而血小板计数(PLT)、血小板压积(PCT)、血小板平均容积(MPV)、血小板体积分布宽度(PDW)与正常对照组之间差异有显著性(P＜0.05),而与ANLL差异无显著性(P＞0.05).结论 MDS患者的骨髓巨核细胞系统改变与ANLL的巨核细胞系统的改变有相关性,而巨核细胞系统的改变有助于对MDS的鉴别.     

糖尿病患者红细胞平均体积和血小板各参数的临床意义

目的探讨糖尿病患者红细胞平均体积和血小板各参数的变化.方法采用全自动五分类血细胞分析仪对92例糖尿病患者和106例健康对照组分别用抗凝血标本进行血细胞检测.结果糖尿病患者抗凝血标本血细胞分析中,MCV、PDW、MPV、P-LCR值均增高,与对照组比较有显著差异(P＜0.05或P＜0.01).而RDW值与对照组比较无显著差异(P＞0.05).结论MCV、PDW、MPV和P-LCR的升高可提示临床,在预示糖尿病微血管病变的发展中起到重要作用.     

慢性高原病患者骨髓造血细胞凋亡及caspase-8和caspase-9表达研究

目的 探讨慢性高原病( CMS)患者骨髓造血细胞凋亡指数及caspase-8和caspase-9mRNA表达变化的意义.方法 选取18例CMS患者,采用末端脱氧核苷酸转移酶介导的dUTP缺口标记(TUNEL)技术定量研究骨髓单个核细胞(BMMNC)凋亡指数,同时采用RT-PCR半定量方法检测BMMNC caspase-8和caspase-9 mRNA的表达.以16例骨科单纯骨折患者为对照.结果 ①CMS患者BMMNC凋亡指数[(8.51±3.35)％]明显低于对照组[(16.00±4.28)％](P＜0.01).②CMS患者caspase-8和caspase-9 mRNA的相对表达水平分别为0.28 ±0.07和0.23±0.08,对照组分别为0.45±0.09和0.41±0.09,CMS组均明显低于对照组(P值均＜0.01).③CMS患者caspase-8和caspase-9mRNA表达水平与血红蛋白浓度呈负相关(r值分别为-0.520及-0.610,P值均＜0.05),与凋亡指数均未发现明显相关性(P值均＞0.05),CMS患者凋亡指数与血红蛋白浓度呈负相关(r=-0.890,P＜0.01).结论 CMS患者BMMNC凋亡指数及caspase-8和caspase-9表达水平均降低,提示CMS患者骨髓造血细胞凋亡减少,caspase-8和caspase-9均参与CMS骨髓造血细胞凋亡异常机制.     

再生障碍性贫血患者骨髓自然杀伤T细胞体外活化特性研究

目的 研究再生障碍性贫血(再障)患者骨髓中自然杀伤T(NKT)细胞的数量以及体外活化后的功能状态.方法 将扩增活化骨髓单个核细胞(BMMNC)中NKT细胞的培养体系分为2组:①加入α-半乳糖神经酰胺(α-galactosylceramide,α-Galcer)+rhIL-2;②加入α-Galcer+rhIL-2+rhGCSF.以流式细胞术(FACS)检测再障患者及正常对照组BMMNC中TCRVα24+Vβ11+细胞(NKT细胞)扩增前后的比率,同时测定NKT细胞活化后胞内IFN-γ、IL-4的表达.结果 再障患者组BMMNC中NKT细胞的比率为(0.19±0.09)%,NKT细胞在①、②培养体系中扩增活化7 d后,扩增倍数分别为79.91±40.56和67.45±29.42(P＜0.05);活化后NKT细胞胞内IFN-γ阳性的比率分别为(62.31±14.67)%和(37.45±7.89)%(P＜0.01);IL-4阳性的比率分别为(27.03±9.88)%和(55.11±12.13)%(P＜0.01).正常对照组BMMNC中NKT细胞的比率为(0.25±0.12)%,较再障患者组显著升高(P＜0.05),正常对照组NKT细胞在相应的①、②培养体系中的扩增倍数均高于再障患者组(P＜0.05);活化后NKT细胞胞内IFN-γ的表达均低于再障患者组(P＜0.05).结论 再障患者骨髓中NKT细胞较正常对照显著减少,扩增能力较正常对照降低,活化后IFN-γ的表达较正常对照升高.在rhG-CSF作用下,再障患者骨髓中NKT细胞经α-Galcer刺激后的扩增能力下降,表达IL-4的NKT2型细胞优势扩增,IL-4表达及分泌增加.     

IL—6基因转染的骨髓基质细胞系对骨髓移植小鼠造血功能恢复？…

目的：探讨白细胞介素６（ＩＬ－６）基因转染的骨髓基质细胞系ＱＸＭＳＣ１ＩＬ－６对骨髓移植后造血功能的重建作用。方法：将骨髓造血细胞和骨髓基质细胞系一起经尾静脉注射给同系小鼠，建立骨髓移植（ＢＭＴ）模型。小鼠的造血功能用脾结节（ＣＦＵ－Ｓ）、粒－单系祖细胞（ＣＦＵ－ＧＭ）、红系祖细胞（ＣＦＵ－Ｅ、ＢＦＵ－Ｅ）测定及外周血各项血液学指标来确定。结果：ＷＸＭＳＣ１ＩＬ－６转基因骨髓基质细胞可明显增强ＢＭ     

IL-6基因转染的骨髓基质细胞系对骨髓移植小鼠造血功能恢复的促进作用

目的:探讨白细胞介素6(IL-6)基因转染的骨位基质细胞系QXMSC, IL6对骨髓移植后造血功能的重建作用。方法:将骨髓造血细胞和骨髓基质细胞系一起经尾静脉注射给同系小鼠,建立骨髓移植(BMT)模型。小鼠的造血功能用脾结节(CFU-S)、粒-单系祖细胞(CFU-GM)、红系祖细胞(CFU-E、BFU-E)测定及外周血各项血液学指标来确定。结果:QXMSC_1 IL-6转基因骨髓基质细胞可明显增强BMT小鼠形成的CFU-S、CFU-GM、CFU-E和BFU-E数,促进外周血象的恢复。结论:QXMSC_1 IL-6细胞可明显促进小鼠骨髓移植后早期造血功能重建。     

再生障碍性贫血患者骨髓造血干/祖细胞体外增殖分化特征的研究

OBJECTIVE: To investigate the quality of bone marrow stem cells from aplastic anemia patients and their in vitro responses to hemopoietic growth factors(HGF). METHODS: CD34 positive bone marrow cells from 10 chronic aplastic anemia(CAA), 5 severe aplastic anemia(SAA) patients and 5 healthy subjects were detected with immunoflurescence assay, enriched by Panning way, and then cultured in vitro for CFU-GM, BFU-E and CFU-E in the presence of recombinant HGFs. RESULTS: CD34 positive rates of the bone marrow mononuclear cells(MNC) of CAA, SAA and control groups were (1.05 +/- 0.51)%, (0.70 +/- 0.37)% and (1.27 +/- 0.45)%, respectively, and there was no difference among them (P > 0.05). After being enriched, CD34 positive cells in MNC of CAA, SAA and control groups increased to a similar level(P > 0.05). In the presence of G-CSF or GM-CSF, the enriched CD34 positive MNC of CAA and SAA patients formed similar CFU-GM number to those of normal controls. The numbers of BFU-E and CFU-E formed from the enriched CD34 positive MNC of CAA and SAA patients were also the same as that of normal control groups under the stimulation of erythropoietin and interleukin-3. Stem cell factor could cooperate with G-CSF, GM-CSF, and erythropoietin significantly increasing the numbers of CFU-GM, BFU-E and CFU-E of CAA, SAA and normal control's enriched CD34 positive MNC. CONCLUSION: The bone marrow CD34 positive cells from aplastic anemia patients appears to be normal in percentages and in in vitro proliferation/differentiation capacities.     

严重型再生障碍性贫血患者骨髓造血祖细胞集落形成与免疫抑…

OBJECTIVE: To explore the defect of hematopoietic stem cell and analyze the relationship between the colony formation capacity of bone marrow hematopoietic progenitor cells and the results of immunosuppressive therapy (IST) in severe aplastic anemia (SAA) patients. METHODS: Methylcellulose semisolid culture was used. RESULTS: Thirty patients with SAA at diagnosis were studied. In 90% of the patients, the CFU-E and CFU-GM yields were strikingly decreased and in 56.7% of the patients there was no colony formation at all. Nevertheless, there was still 10% of the patients having normal CFU-E, BFU-E or/ and CFU-GM yields. After IST, 59.1% of the patients showed colony formation improvement. The difference between the results obtained pre- and post-IST(for CFU-E and BFU-E, P < 0.01, for CFU-GM, P < 0.05) was significant. In the majority of the patients, the colony formation capacities were still under the normal post-IST. Moreover, 22.7% of the patients remained no colony formation post-IST. The IST response rates between the patients with or without colony formation had no statistically difference (80% versus 50%, P < 0.05). The increment of colony formation appeared later than the therapeutic effect did, but frequently concurred with the appearance of magkaryocytes in the bone marrow smear. CONCLUSION: In the majority of SAA patients, the hematopoietic stem cells or progenitors were defective perhaps caused by immune damage; IST can improve the hematopoiesis in vitro and in vivo of SAA patients.     

Three-lineage hemopoietic precursor cells and effectiveness of recombinant human erythropoietin in patients with myelodysplastic syndromes.

Four-stem-cell assays, which evaluate megakaryocytic (CFU-Meg), immature and mature erythropoietic (BFU-E, CFU-E), and granulocyte-macrophage (CFU-GM) colony formation, were performed in nine patients with myelodysplastic syndromes (MDS). The CFU-Meg, BFU-E, and CFU-E colony growths were disturbed more often than the CFU-GM colony formation. A CFU-E increase was not recognized in most MDS patients, but a dose-dependent increase of bone marrow CFU-Es in response to erythropoietin (EPO) was recognized only in two refractory anemia (RA) patients whose CFU-Es were more than one tenth of normal controls. One patient with RA and the other with chronic myelomonocytic leukemia (CMML), both of whose bone marrow CFU-Es did not increase at the higher dose of EPO in vitro, were treated with recombinant human EPO (rHuEPO), resulting in no effects. The responsiveness of patients with MDS to various recombinant hemopoietic factors might be predicted by both the residual degree of bone marrow hematopoietic precursor cells and the response of stem cells to the higher doses of each hemopoietic factor.     

骨髓基质细胞系QXMSC_1体外促进造血及其作用机理的研究

本实验研究了骨髓基质细胞系QXMSC_1体外对CFU-F,CFU-GM,BFU-E及CFU-E集落形成的影响,并通过建立QXMSC_1基质细胞与骨髓造血细胞的长期共培养体系,研究了QXMSC-1在体外促进造血的机理。结果表明,QXMSC_1基质细胞条件培养上清液可促进小鼠CFU-F,CFU-GM,BFU-E及CFU-E集落的生长。在无GM-CSF和Epo存在的情况下,QXMSC_1细胞能维持CFU-GM,BFU-E和CFU-E集落生长。表明QXMSC_1细胞本身可分泌GM-CSF和Epo。QXMSC_1细胞与骨髓造血细胞共培养时,可明显提高CFU-GM集落数。共培养体系中,用微孔滤膜隔断QXMSC_1与造血细胞的直接接触,也能促进CFU-GM集落生成,但比混合培养时低,说明QXMSC_1通过直接接触和分泌细胞因子促进造血的过程。     

Reinjection of ex vivo-expanded primate bone marrow mononuclear cells strongly reduces radiation-induced aplasia

To assess the therapeutic efficacy of ex vivo-expanded hematopoietic cells in the treatment of radiation-induced pancytopenia, we have set up a non-human primate model. Two ex vivo expansion protocols for bone marrow mononuclear cells (BMMNC) were studied. The first consisted of a 7-day culture in the presence of stem cell factor (SCF), Flt3-ligand, thrombopoietin (TPO), interleukin-3 (IL-3), and IL-6, which induced preferentially the expansion of immature hematopoietic cells [3.1 +/- 1.4, 10.0 +/- 5.1, 2.2 +/- 1.9, and 1.0 +/- 0.3-fold expansion for mononuclear cells (MNC), colony-forming units-granulocyte-macrophage (CFU-GM), burst-forming units erythroid (BFU-E), and long-term culture initiating cells (LTC-IC) respectively]. The second was with the same cytokine combination supplemented with granulocyte colony-stimulating factor (G-CSF) with an increased duration of culture up to 14 days and induced mainly the production of mature hematopoietic cells (17.2 +/- 11.7-fold expansion for MNC and no detectable BFU-E and LTC-IC), although expansion of CFU-GM (13.7 +/- 18.8-fold) and CD34+ cells (5.2 +/- 1.4-fold) was also observed. Results showed the presence of mesenchymal stem cells and cells from the lymphoid and the megakaryocytic lineages in 7-day expanded BMMNC. To test the ability of ex vivo-expanded cells to sustain hematopoietic recovery after radiation-induced aplasia, non-human primates were irradiated at a supralethal dose of 8 Gy and received the product of either 7-day (24 h after irradiation) or 14-day (8 days after irradiation) expanded BMMNC. Results showed that the 7-day ex vivo-expanded BMMNC shortened the period and the severity of pancytopenia and improved hematopoietic recovery, while the 14 day ex vivo-expanded BMMNC mainly produced a transfusion-like effect during 8 days, followed by hematopoietic recovery. These results suggest that ex vivo expanded BMMNC during 7 days may be highly efficient in the treatment of radiation-induced aplasia.     

阵发性睡眠性血红蛋白尿症患者骨髓造血细胞对粒细胞集落刺激因子反应的研究

目的　观察阵发性睡眠性血红蛋白尿症(PNH)患者骨髓造血细胞对粒细胞集落刺激因子(G CSF)的反应并研究其机制。方法　①用半固体培养基体外培养17例PNH患者和12名正常人骨髓单个核细胞(BMMNC),观察加与不加G CSF两组粒单核细胞集落(CFU GM)和集簇(cFU GM)形成情况。PNH患者骨髓GPI+CD34+和GPI-CD34+细胞表达粒细胞集落刺激因子受体(G CSFR、CD114)和干细胞生长因子受体(C KIT、CD117)的差异。②用流式细胞术检测20例初发PNH患者和12名正常对照BMMNC和CD34+细胞表面GPI锚定蛋白CD59以及CD114和CD117的表达。结果　①无G CSF及加G CSF培养PNH组cFU GM数量分别为( 112. 41±22. 74 )和( 133. 82±25. 85 ) /105BMMNC,均较正常对照的(190. 33±36. 05)和(309. 42±92. 94) /105 BMMNC少(P<0. 05);无G CSF及加G CSF培养PNH组CFU GM数量分别为(24. 29±9. 05)和(27. 53±10. 65) /105 BMMNC,也较正常对照的(77. 42±36. 01)和(98. 00±43. 14) /105 BMMNC少(P<0. 05 )。PNH组加G CSF后,cFU GM增加率为(20. 29±6. 82)% (P<0. 05),CFU GM增加率为(16. 45±3. 28)% (P>0. 05)。正常对照加G CSF后,cFU GM增加率为(56. 11±37. 59)%,CFU GM增加率为(48. 03±13. 60)% (P值均<0. 05),PNH组增加率均低于正常对照(P<0